FLOW CYTOMETRIC MONITORING OF NORMAL PLASMA CELLS AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MULTIPLE MY-ELOMA (MM)
Persistence of abnormal neoplastic plasma cells (APLs) detectable by flow cytometry at Ͼ 3 months after autografting for MM has been reported to predict early disease progression. In this study, we retrospectively reviewed the flow cytometric data from bone marrow aspirates from MM patients before and after autologous stem cell transplantation (ASCT). CD38 expression was used to identify plasma cells, and CD19/CD45/CD56 expression was used to distinguish normal plasma cells (NPCs) from APCs. A minimum of 30 events that satisfied the gating strategy were required. Conventional response criteria (Blade criteria) and survival data were also collected. A total of 34 patients treated with the same conditioning regimen were screened between May 2001 and April 2004, but only 26 of these patients had adequate flow cytometric data before and after ASCT, whereas 31 patients had data available between 8 weeks and 12 months after ASCT. Median follow-up from ASCT was 12 months. NPCs and APCs were present in 42% (11 of 26) and 54% (14 of 26) of patients after ASCT compared to 12.5% and 67% before ASCT. There were 14 patients in CR/VGPR after ASCT, compared to only 6 before ASCT. No correlation was found between the presence of APCs or NPCs and response status, PFS, or OS. However, of the 15 patients with an APC:NPC ratio Յ 1, 67% had CR/VGPR, and of the 11 patients with an APC:NPC ratio Ͼ 1, 36% had CR/VGPR. Using the method of Kaplan and Meier, the median PFS for patients with an APC:NPC ratio &le: 1 has not been reached, whereas the median PFS for the rest of patients was 18 months (P ϭ .0896). OS has not been reached for either group. In conclusion, recovery of NPCs after ASCT is seen in a significant number of patients and may serve as another predictor of better PFS in MM patients. Skikne, B., Thudi, N., Deauna-Limayo, D., Ganguly, S., Bodensteiner, D., Devine, C., Cook, J.D. Kansas University Medical Center, Kansas City, KS. Patients with stage III-IV Hodgkin's lymphoma (HL) or with bulky stage I/II disease have a relapse rate of 30%-40% after primary treatment. High-dose chemotherapy with stem cell transplantation (Tx) is a treatment option after relapse or in those with primary induction failure. In the present study, we examined longterm outcomes in 45 relapsed/primary induction failure HL patients undergoing autologous peripheral stem cell (25 patients), bone marrow (17) or combination (3) Tx between 1985 and December 2003. The median age was 32 years (range, 16 -64 years); 38 patients had nodular sclerosing HL;, 17 had stage I/II disease, 13 had stage III disease, and 15 had stage IV disease; and 33 had B symptoms at diagnosis. Twenty patients were previously treated with 1-2 prior regimens, while 25 had Ն 3 treatment regimens. Sixteen patients had sensitive disease to salvage therapy prior to Tx, 27 had resistance to salvage therapy, and 2 did not undergo pre-Tx salvage therapy. Five patients had primary resistant disease, 33 had relapsed disease, and 7 were in CR at the time of Tx. CBV was used in 30 patients, BEAM was used in 9, and 5 received CY/TBI-based regimens. Five patients (11%) had early mortality (Ͻ 100 days) directly attributable to the procedure; 4 of these were cardiac related, and 1 was due to infection. The overall response was 93% with CR achieved in 28 (62%) and PR in 14 (31%). The median OS was 5.5 years, and the median DFS was 1 year, with a 5-year DFS in 26%. For patients achieving CR after Tx, 74% remain alive at Ͼ 10 years, and the median survival has not been reached. However, the median PFS was 1.6 years in patients achieving CR after Tx and 9.2 months in those with an incomplete response after Tx (P Ͼ .05). Seventeen patients are alive, 2 are lost to follow-up, and 21 have died. Fourteen (31%) died from disease progression (31%), 2 (4%) died from MDS/AML occurring after 32 and 66 months, 2 (4%) died of late-occurring infections, 2 (4%) died from respiratory failure, and 1 (2%) died from late cardiac failure. OS and DFS did not differ based on peripheral stem cell versus bone marrow Tx, B symptoms at diagnosis, sex differences, age Ͻ 20 years versus Ͼ 20 years, or high-dose therapy regimens, but a difference in OS (P ϭ .04) and DFS (P ϭ .03) was seen in patients transplanted in CR versus those transplanted in active disease. Patients with sensitive disease to salvage therapy before Tx did show a trend toward improved OS and DFS, but this was not significant. High-dose chemotherapy and autologous stem cell Tx can lead to prolonged DFS in 25%-35% of patients.
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